DNA Script signed distribution agreements with Gencell, Bio‑Medical Science Co. (BMS), and BioStream to expand global access to its benchtop SYNTAX platform for on‑demand single‑strand DNA oligo synthesis. Gencell will cover Latin America, BMS South Korea, and BioStream Japan, enabling decentralized DNA production without reliance on overseas synthesis hubs. The deals support faster local turnaround for oligonucleotide needs in research and diagnostics. DNA Script CEO Marc Montserrat framed the expansion as part of a strategy to scale SYNTAX adoption worldwide and reduce supply‑chain latency for critical synthetic DNA inputs.